无创迷走神经刺激作为偏头痛急性治疗:随机PRESTO研究
这项多中心、双盲、随机、假刺激对照试验纳入248例发作性偏头痛患者,在疼痛发作20分钟内接受无创迷走神经刺激(nVNS)或假刺激。nVNS组在首次治疗发作后30分钟和60分钟无痛率显著优于假刺激组,但120分钟主要终点未达统计学显著;nVNS安全且耐受性良好。
要点
- nVNS组30分钟无痛率12.7% vs 假刺激组4.2%(p=0.012),60分钟21.0% vs 10.0%(p=0.023)。
- 120分钟主要终点无痛率30.4% vs 19.7%(p=0.067),未达统计学显著。
- 事后重复测量分析显示nVNS在30、60、120分钟有治疗获益(OR 2.3;95%CI 1.2, 4.4;p=0.012)。
核心结论
- 这项随机假刺激对照试验支持nVNS在偏头痛发作后早至30分钟至60分钟的终止发作疗效,并提示其疼痛缓解、耐受性和实用性。
研究设计与样本
- 多中心、双盲、随机、假刺激对照试验,纳入248例伴或不伴先兆的发作性偏头痛患者,随机接受nVNS或假刺激,于疼痛发作20分钟内使用,若15分钟内疼痛未改善则重复治疗。
主要发现
- 首次治疗发作后30分钟无痛率nVNS组(n=120)12.7% vs 假刺激组(n=123)4.2%(p=0.012)。
- 首次治疗发作后60分钟无痛率nVNS组21.0% vs 假刺激组10.0%(p=0.023)。
- 首次治疗发作后120分钟主要终点无痛率nVNS组30.4% vs 假刺激组19.7%(p=0.067;逻辑回归),未达统计学显著。
- 事后重复测量分析显示nVNS在30、60、120分钟的治疗获益(OR 2.3;95%CI 1.2, 4.4;p=0.012)。
- nVNS在包括120分钟疼痛缓解在内的其他终点显示获益,且安全、耐受性良好。
关键数值与推荐
- 无痛率30分钟:nVNS组12.7% vs 假刺激组4.2%(p=0.012)。
- 无痛率60分钟:nVNS组21.0% vs 假刺激组10.0%(p=0.023)。
- 无痛率120分钟(主要终点):nVNS组30.4% vs 假刺激组19.7%(p=0.067)。
- 事后重复测量分析OR 2.3;95%CI 1.2, 4.4;p=0.012。
- 证据等级:Class I证据表明nVNS显著增加发作性偏头痛患者刺激后2小时轻度疼痛或无痛的概率(绝对差13.2%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy, safety, and tolerability of noninvasive vagus nerve stimulation (nVNS; gammaCore; electroCore, LLC, Basking Ridge, NJ) for the acute treatment of migraine in a multicenter, double-blind, randomized, sham-controlled trial. METHODS: A total of 248 participants with episodic migraine with/without aura were randomized to receive nVNS or sham within 20 minutes from pain onset. Participants were to repeat treatment if pain had not improved in 15 minutes. RESULTS: nVNS (n = 120) was superior to sham (n = 123) for pain freedom at 30 minutes (12.7% vs 4.2%; p = 0.012) and 60 minutes (21.0% vs 10.0%; p = 0.023) but not at 120 minutes (30.4% vs 19.7%; p = 0.067; primary endpoint; logistic regression) after the first treated attack. A post hoc repeated-measures test provided further insight into the therapeutic benefit of nVNS through 30, 60, and 120 minutes (odds ratio 2.3; 95% confidence interval 1.2, 4.4; p = 0.012). nVNS demonstrated benefits across other endpoints including pain relief at 120 minutes and was safe and well-tolerated. CONCLUSION: This randomized sham-controlled trial supports the abortive efficacy of nVNS as early as 30 minutes and up to 60 minutes after an attack. Findings also suggest effective pain relief, tolerability, and practicality of nVNS for the acute treatment of episodic migraine. CLINICALTRIALSGOV IDENTIFIER: NCT02686034. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that for patients with an episodic migraine, nVNS significantly increases the probability of having mild pain or being pain-free 2 hours poststimulation (absolute difference 13.2%).
引用
- Tassorelli C, Grazzi L, de Tommaso M, et al. Noninvasive vagus nerve stimulation as acute therapy for migraine: The randomized PRESTO study. Neurology. 2018. PMID: 29907608. doi:10.1212/WNL.0000000000005857
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。